Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EPS (Weighted Average and Diluted) (2020 - 2025)

Historic EPS (Weighted Average and Diluted) for Exagen (XGN) over the last 6 years, with Q3 2025 value amounting to -$0.31.

  • Exagen's EPS (Weighted Average and Diluted) fell 1071.43% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.92, marking a year-over-year increase of 212.77%. This contributed to the annual value of -$0.83 for FY2024, which is 3803.32% up from last year.
  • As of Q3 2025, Exagen's EPS (Weighted Average and Diluted) stood at -$0.31, which was down 1071.43% from -$0.21 recorded in Q2 2025.
  • In the past 5 years, Exagen's EPS (Weighted Average and Diluted) registered a high of -$0.16 during Q2 2024, and its lowest value of -$0.88 during Q4 2022.
  • Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.31 (2023), whereas its average is -$0.39.
  • As far as peak fluctuations go, Exagen's EPS (Weighted Average and Diluted) crashed by 12631.58% in 2022, and later skyrocketed by 6744.19% in 2023.
  • Exagen's EPS (Weighted Average and Diluted) (Quarter) stood at -$0.44 in 2021, then plummeted by 100.41% to -$0.88 in 2022, then soared by 64.97% to -$0.31 in 2023, then soared by 33.35% to -$0.21 in 2024, then plummeted by 50.04% to -$0.31 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$0.31 in Q3 2025, compared to -$0.21 in Q2 2025 and -$0.2 in Q1 2025.